ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q3 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $2.93 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• The Lovesac Co. (LOVE) PT Raised to $20 at DA Davidson Following Q1 Results
• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO